Showing results (1421-1430 of 2,879) with videos related to
Sort By:
Pageof 288
Molecular Diversity|March 15, 2019
Two- and three-dimensional QSAR studies on hURAT1 inhibitors with flexible linkers: topomer CoMFA and HQSARTingting Zhao, Zean Zhao, Fengting Lu, et al.Molecular Diversity|February 25, 2019
Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1Priya Mahajan, Bhumika Wadhwa, Manas Ranjan Barik, et al.Molecular Diversity|September 6, 2019
Synthesis and in vitro anti-Toxoplasma gondii activity of a new series of aryloxyacetophenone thiosemicarbazonesMahsa Ansari, Mahbobeh Montazeri, Ahmad Daryani, et al.Molecular Diversity|September 9, 2019
One-pot synthesis of substituted pyrrole-imidazole derivatives with anticancer activityMing Zhang, Yong Ding, Hong-Xia Qin, et al.Molecular Diversity|January 15, 2021
Photooxidation of 2,3-dihydroquinazolin-4(1H)-ones: retention or elimination of 2-substitutionHamid Reza Memarian, Reza AghalarMolecular Diversity|February 6, 2021
Synthesis and fungicidal activity of methyl (E)-1-(2-((E)-2-methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)-2-(1-arylidene)hydrazine-1-carboxylates †‡Xuelian Liu, Changqing Jia, Fahong Yin, et al.Molecular Diversity|January 3, 2022
A critical analysis of urea transporter B inhibitors: molecular fingerprints, pharmacophore features for the development of next-generation diureticsSk Abdul Amin, Sudipta Nandi, Sushil Kumar Kashaw, et al.Molecular Diversity|January 19, 2022
Synthesis and in vitro evaluation of antitumor activity of spiro[indolo[2,1-b]quinazoline-pyrano[2,3-d]pyrimidine] and spiro[indolo[2,1-b]quinazoline-pyrido[2,3-d]pyrimidine] derivatives by using 2D and 3D cell culture modelsZahra Sadeghian, Mohammad Bayat, Fatemeh SafariMolecular Diversity|January 9, 2022
Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2Avinash Mishra, Anurag S RathoreMolecular Diversity|January 10, 2022
A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing studyJurica Novak, Vladimir A PotemkinPageof 288